159 related articles for article (PubMed ID: 24992675)
21. MCL-1 is modulated in Crohn's disease fibrosis by miR-29b via IL-6 and IL-8.
Nijhuis A; Curciarello R; Mehta S; Feakins R; Bishop CL; Lindsay JO; Silver A
Cell Tissue Res; 2017 May; 368(2):325-335. PubMed ID: 28190086
[TBL] [Abstract][Full Text] [Related]
22. MiR-1307 promotes ovarian cancer cell chemoresistance by targeting the ING5 expression.
Chen WT; Yang YJ; Zhang ZD; An Q; Li N; Liu W; Yang B
J Ovarian Res; 2017 Jan; 10(1):1. PubMed ID: 28086946
[TBL] [Abstract][Full Text] [Related]
23. Expression of miR-224-5p is associated with the original cisplatin resistance of ovarian papillary serous carcinoma.
Zhao H; Bi T; Qu Z; Jiang J; Cui S; Wang Y
Oncol Rep; 2014 Sep; 32(3):1003-12. PubMed ID: 25017423
[TBL] [Abstract][Full Text] [Related]
24. MicroRNA-630 inhibitor sensitizes chemoresistant ovarian cancer to chemotherapy by enhancing apoptosis.
Eoh KJ; Lee SH; Kim HJ; Lee JY; Kim S; Kim SW; Kim YT; Nam EJ
Biochem Biophys Res Commun; 2018 Mar; 497(2):513-520. PubMed ID: 29452092
[TBL] [Abstract][Full Text] [Related]
25. Boosting the apoptotic response of high-grade serous ovarian cancers with CCNE1 amplification to paclitaxel in vitro by targeting APC/C and the pro-survival protein MCL-1.
Raab M; Kobayashi NF; Becker S; Kurunci-Csacsko E; Krämer A; Strebhardt K; Sanhaji M
Int J Cancer; 2020 Feb; 146(4):1086-1098. PubMed ID: 31286496
[TBL] [Abstract][Full Text] [Related]
26. Hypoxia-induced up-regulation of miR-27a promotes paclitaxel resistance in ovarian cancer.
Feng L; Shen F; Zhou J; Li Y; Jiang R; Chen Y
Biosci Rep; 2020 Apr; 40(4):. PubMed ID: 32190895
[TBL] [Abstract][Full Text] [Related]
27. mir-29 regulates Mcl-1 protein expression and apoptosis.
Mott JL; Kobayashi S; Bronk SF; Gores GJ
Oncogene; 2007 Sep; 26(42):6133-40. PubMed ID: 17404574
[TBL] [Abstract][Full Text] [Related]
28. miR-375 is upregulated in acquired paclitaxel resistance in cervical cancer.
Shen Y; Wang P; Li Y; Ye F; Wang F; Wan X; Cheng X; Lu W; Xie X
Br J Cancer; 2013 Jul; 109(1):92-9. PubMed ID: 23778521
[TBL] [Abstract][Full Text] [Related]
29. BAG3 epigenetically regulates GALNT10 expression via WDR5 and facilitates the stem cell-like properties of platin-resistant ovarian cancer cells.
Zhao FY; Zhang Q; Wang JM; Jiang JY; Huyan LY; Liu BQ; Yan J; Li C; Wang HQ
Biochim Biophys Acta Mol Cell Res; 2021 Aug; 1868(9):119077. PubMed ID: 34111434
[TBL] [Abstract][Full Text] [Related]
30. Combinatorial effects of miR-20a and miR-29b on neuronal apoptosis induced by spinal cord injury.
Liu XJ; Zheng XP; Zhang R; Guo YL; Wang JH
Int J Clin Exp Pathol; 2015; 8(4):3811-8. PubMed ID: 26097563
[TBL] [Abstract][Full Text] [Related]
31. Long non-coding RNA UCA1 promotes the progression of paclitaxel resistance in ovarian cancer by regulating the miR-654-5p/SIK2 axis.
Li ZY; Wang XL; Dang Y; Zhu XZ; Zhang YH; Cai BX; Zheng L
Eur Rev Med Pharmacol Sci; 2020 Jan; 24(2):591-603. PubMed ID: 32016960
[TBL] [Abstract][Full Text] [Related]
32. BAG3 regulates stability of IL-8 mRNA via interplay between HuR and miR-4312 in PDACs.
Li C; Jiang JY; Wang JM; Sun J; An MX; Li S; Yan J; Wang HQ
Cell Death Dis; 2018 Aug; 9(9):863. PubMed ID: 30154469
[TBL] [Abstract][Full Text] [Related]
33. Bcl-2-associated athanogene 3(BAG3) is associated with tumor cell proliferation, migration, invasion and chemoresistance in colorectal cancer.
Li N; Chen M; Cao Y; Li H; Zhao J; Zhai Z; Ren F; Li K
BMC Cancer; 2018 Aug; 18(1):793. PubMed ID: 30081850
[TBL] [Abstract][Full Text] [Related]
34. The miR-200 family controls beta-tubulin III expression and is associated with paclitaxel-based treatment response and progression-free survival in ovarian cancer patients.
Leskelä S; Leandro-García LJ; Mendiola M; Barriuso J; Inglada-Pérez L; Muñoz I; Martínez-Delgado B; Redondo A; de Santiago J; Robledo M; Hardisson D; Rodríguez-Antona C
Endocr Relat Cancer; 2011 Feb; 18(1):85-95. PubMed ID: 21051560
[TBL] [Abstract][Full Text] [Related]
35. Role of microRNAs in drug-resistant ovarian cancer cells.
Sorrentino A; Liu CG; Addario A; Peschle C; Scambia G; Ferlini C
Gynecol Oncol; 2008 Dec; 111(3):478-86. PubMed ID: 18823650
[TBL] [Abstract][Full Text] [Related]
36. Role of microRNA-29b in myelodysplastic syndromes during transformation to overt leukaemia.
Kirimura S; Kurata M; Nakagawa Y; Onishi I; Abe-Suzuki S; Abe S; Yamamoto K; Kitagawa M
Pathology; 2016 Apr; 48(3):233-41. PubMed ID: 27020498
[TBL] [Abstract][Full Text] [Related]
37. Knockdown of BAG3 sensitizes bladder cancer cells to treatment with the BH3 mimetic ABT-737.
Mani J; Antonietti P; Rakel S; Blaheta R; Bartsch G; Haferkamp A; Kögel D
World J Urol; 2016 Feb; 34(2):197-205. PubMed ID: 26100943
[TBL] [Abstract][Full Text] [Related]
38. MicroRNA profile of paclitaxel-resistant serous ovarian carcinoma based on formalin-fixed paraffin-embedded samples.
Li X; Lu Y; Chen Y; Lu W; Xie X
BMC Cancer; 2013 Apr; 13():216. PubMed ID: 23627607
[TBL] [Abstract][Full Text] [Related]
39. Downregulation of miR-363 increases drug resistance in cisplatin-treated HepG2 by dysregulating Mcl-1.
Ou Y; Zhai D; Wu N; Li X
Gene; 2015 Nov; 572(1):116-122. PubMed ID: 26143754
[TBL] [Abstract][Full Text] [Related]
40. The role of the MAD2-TLR4-MyD88 axis in paclitaxel resistance in ovarian cancer.
Bates M; Spillane CD; Gallagher MF; McCann A; Martin C; Blackshields G; Keegan H; Gubbins L; Brooks R; Brooks D; Selemidis S; O'Toole S; O'Leary JJ
PLoS One; 2020; 15(12):e0243715. PubMed ID: 33370338
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]